HK1116803A1 - Novel anti-plgf antibody - Google Patents

Novel anti-plgf antibody

Info

Publication number
HK1116803A1
HK1116803A1 HK08102805.3A HK08102805A HK1116803A1 HK 1116803 A1 HK1116803 A1 HK 1116803A1 HK 08102805 A HK08102805 A HK 08102805A HK 1116803 A1 HK1116803 A1 HK 1116803A1
Authority
HK
Hong Kong
Prior art keywords
novel anti
plgf antibody
fragments
plgf
antibody
Prior art date
Application number
HK08102805.3A
Other languages
English (en)
Inventor
Jean-Marie Stassen
Peter Carmeliet
Desire Collen
Original Assignee
Thrombogenics Nv
Life Sciences Res Partners
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv, Life Sciences Res Partners, Vlaams Interuniv Inst Biotech filed Critical Thrombogenics Nv
Publication of HK1116803A1 publication Critical patent/HK1116803A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
HK08102805.3A 2005-03-24 2008-03-11 Novel anti-plgf antibody HK1116803A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66476805P 2005-03-24 2005-03-24
PCT/BE2006/000023 WO2006099698A2 (en) 2005-03-24 2006-03-24 Novel anti-plgf antibody

Publications (1)

Publication Number Publication Date
HK1116803A1 true HK1116803A1 (en) 2009-01-02

Family

ID=36928446

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102805.3A HK1116803A1 (en) 2005-03-24 2008-03-11 Novel anti-plgf antibody

Country Status (27)

Country Link
US (3) US7875704B2 (no)
EP (2) EP1869085B1 (no)
JP (2) JP5164829B2 (no)
KR (1) KR101314014B1 (no)
CN (1) CN101184776B (no)
AT (1) ATE549358T1 (no)
AU (2) AU2006227571B8 (no)
BR (1) BRPI0609151B8 (no)
CA (1) CA2601267C (no)
CY (1) CY1113224T1 (no)
DK (1) DK1869085T3 (no)
EA (1) EA013970B1 (no)
ES (2) ES2384110T3 (no)
HK (1) HK1116803A1 (no)
HR (1) HRP20120477T1 (no)
IL (1) IL185754A (no)
ME (1) ME01446B (no)
MX (1) MX2007011735A (no)
NO (1) NO341877B1 (no)
NZ (1) NZ561763A (no)
PL (1) PL1869085T3 (no)
PT (1) PT1869085E (no)
RS (1) RS52372B (no)
SI (1) SI1869085T1 (no)
UA (1) UA94707C2 (no)
WO (1) WO2006099698A2 (no)
ZA (1) ZA200707258B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297016B1 (en) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
ES2592902T3 (es) 2008-10-02 2016-12-02 Vib Vzw Inhibición del PlGF para el tratamiento de la leucemia positiva para el cromosoma Filadelfia
CN102265157B (zh) * 2008-12-23 2014-11-26 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
IN2012DN02737A (no) 2009-09-01 2015-09-11 Abbott Lab
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5814951B2 (ja) 2010-03-10 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 免疫グロブリン溶液を精製するための方法
KR20130091746A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2785739B1 (en) * 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN104930353B (zh) * 2015-07-10 2017-08-15 浙江大学 一种城市供水管网的调压减漏评估系统
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS HEMAGGLUTININS AND USES THEREOF
EP3606555A4 (en) * 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
CN109134650A (zh) * 2018-09-10 2019-01-04 宁波奥丞生物科技有限公司 抗人plgf单克隆抗体的制备方法
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020260595A1 (en) 2019-06-26 2020-12-30 Oncurious Nv Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
EP3936868A1 (en) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin A ratio between plgf and sflt1 is predictive for neural invasion in patients suffering from pancreatic cancer
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CN112358546B (zh) * 2020-11-10 2022-04-01 宁波奥丞生物科技有限公司 杂交瘤细胞株9c1、plgf-1单克隆抗体及其应用
WO2022099465A1 (zh) * 2020-11-10 2022-05-19 宁波奥丞生物科技有限公司 杂交瘤细胞株9c1、plgf-1单克隆抗体及其制备方法和应用
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
CN113999310A (zh) * 2020-12-30 2022-02-01 江苏普若维生物技术有限责任公司 一种plgf单克隆抗体、试剂盒、其制备方法和应用
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2023118294A1 (en) 2021-12-22 2023-06-29 Vib Vzw Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
WO1993020229A1 (en) 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2235685A1 (en) 1995-10-23 1997-05-01 Hyal Pharmaceutical Australia Limited Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
JP2001501471A (ja) 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド 血管新生の阻害のための遺伝子治療
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
JPH11302193A (ja) * 1998-04-22 1999-11-02 Toagosei Co Ltd 血管新生阻害剤
EP1079688A1 (en) 1998-05-26 2001-03-07 Innogenetics N.V. Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
JP2001086982A (ja) 1999-07-16 2001-04-03 Shunpei Niida 骨吸収調節薬
WO2001057067A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
EP1297016B1 (en) 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
US7139817B1 (en) * 2001-06-12 2006-11-21 Network Appliance, Inc. Managing configuration information for multiple devices
CA2450954A1 (en) 2001-06-20 2003-01-03 Imclone Systems Incorporated Method of treating atherosclerosis and other inflammatory diseases
ATE347908T1 (de) 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
US7700571B2 (en) 2002-06-05 2010-04-20 Genentech, Inc. Compositions and methods for liver growth and liver protection
EP1517703B1 (en) 2002-06-28 2007-03-21 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Placental growth factor as a target for the treatment of osteoporosis
JP2006505268A (ja) * 2002-11-08 2006-02-16 プリマゲン ホールディング ベー．フェー． 少なくとも２つの核酸配列間の比率を定量化する方法
US20050250801A1 (en) * 2003-03-10 2005-11-10 Kunwar Shailubhai Method of treating cancer with azaspirane compositions
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
WO2007003609A1 (en) 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
ES2592902T3 (es) 2008-10-02 2016-12-02 Vib Vzw Inhibición del PlGF para el tratamiento de la leucemia positiva para el cromosoma Filadelfia

Also Published As

Publication number Publication date
CN101184776B (zh) 2013-04-24
NO341877B1 (no) 2018-02-12
EP1869085B1 (en) 2012-03-14
EP2447281A1 (en) 2012-05-02
KR101314014B1 (ko) 2013-10-02
US20110123525A1 (en) 2011-05-26
RS52372B (en) 2012-12-31
US20080193455A1 (en) 2008-08-14
JP2012136522A (ja) 2012-07-19
CY1113224T1 (el) 2016-04-13
IL185754A (en) 2013-02-28
KR20080016794A (ko) 2008-02-22
WO2006099698A2 (en) 2006-09-28
SI1869085T1 (sl) 2012-07-31
AU2006227571B8 (en) 2011-01-27
US8758748B2 (en) 2014-06-24
BRPI0609151A2 (pt) 2010-02-17
UA94707C2 (en) 2011-06-10
AU2006227571A1 (en) 2006-09-28
AU2011201340A1 (en) 2011-04-14
PT1869085E (pt) 2012-06-01
JP5164829B2 (ja) 2013-03-21
EA200702064A1 (ru) 2008-02-28
US20140178397A1 (en) 2014-06-26
HRP20120477T1 (hr) 2012-07-31
IL185754A0 (en) 2008-01-06
CN101184776A (zh) 2008-05-21
WO2006099698A3 (en) 2006-11-30
US7875704B2 (en) 2011-01-25
AU2006227571B2 (en) 2010-12-23
US9085617B2 (en) 2015-07-21
ME01446B (me) 2013-12-20
CA2601267A1 (en) 2006-09-28
BRPI0609151B8 (pt) 2021-05-25
JP2008532557A (ja) 2008-08-21
ES2384110T3 (es) 2012-06-29
MX2007011735A (es) 2008-03-14
PL1869085T3 (pl) 2012-09-28
ES2565481T3 (es) 2016-04-05
EA013970B1 (ru) 2010-08-30
NZ561763A (en) 2009-02-28
ATE549358T1 (de) 2012-03-15
NO20074563L (no) 2007-12-18
BRPI0609151B1 (pt) 2020-01-21
CA2601267C (en) 2014-02-18
AU2011201340B2 (en) 2012-02-23
EP2447281B1 (en) 2015-12-16
ZA200707258B (en) 2008-06-25
EP1869085A2 (en) 2007-12-26
DK1869085T3 (da) 2012-06-18

Similar Documents

Publication Publication Date Title
HK1116803A1 (en) Novel anti-plgf antibody
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
UA92504C2 (en) Anti-myostatin monoclonal antibody
EA200870050A1 (ru) Анти-il-17-антитела
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ATE461220T1 (de) Anti-egfr-antikörper
WO2005003169A3 (en) Modified antibody fab fragments
WO2003034903A3 (en) Psma antibodies and protein multimers
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
ATE545657T1 (de) Tgf-beta antikörper
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
SG162829A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
UA94245C2 (en) Anti-il-17 antibodies
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210329